Company Overview
- Headquarters
- 3410 Central Expy, Santa Clara CA
- Website
- xenoport.com
- Phone
- (408) 616-7200
- Employees
- 113
- Founded in
- 1999
- Industry
- Materials/Manufacturing
- NAICS Code
-
NAICS Code 541 CompaniesNAICS Code 54 CompaniesNAICS Code 5417 CompaniesNAICS Code 325 CompaniesNAICS Code 32541 CompaniesNAICS Code 32 CompaniesNAICS Code 3254 Companies
- SIC Code
-
SIC Code 28 CompaniesSIC Code 283 Companies
Financials & Stats
Revenue
$47B
Total Funding Amount
$72M
Who is XenoPort Inc
XenoPort, Inc. is a biopharmaceutical company headquartered in Santa Clara, California. With 113 employees, the company focuses on developing and commercializing treatments for neurological disorders. XenoPort generated $46.9 million in revenue. XenoPort markets Horizant® (gabapentin enacarbil) Extended-Release Tablets in the United States. These tablets are also marketed in Japan by Astellas Pharma Inc. under the brand name Regnite®. XenoPort retains worldwide rights to gabapentin enacarbil outside of Japan. The company’s pipeline of product candidates includes potential treatments for Parkinson’s disease, relapsing-remitting multiple sclerosis, and psoriasis. XenoPort’s focus on internally discovered product candidates allows for a tailored approach to developing treatments for specific neurological conditions. For more information about XenoPort and its products, please visit xenoport.com.
Company Leadership
XenoPort Inc Tech Stack
Companies Similar to XenoPort Inc
Analyze industry trends and opportunities by examining competitors and companies comparable to XenoPort Inc, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 47M | 94 | Delano, MN | 1964 | |
| 46M | 8 | Zion, IL | 1984 | |
| 46M | 233 | Worcester, MA | 1966 | |
| 46M | 112 | Bedford, MA | 1999 | |
| 46M | 64 | Mason, OH | 1908 |